Sun Pharma clocked a net profit of ₹1,391 crore for the three months ended June 30, 2014, compared to a net loss of ₹1,276 crore in the same period last year.
The loss in the first quarter last year was because the company set aside ₹2,517 crore towards settlement on a patent infringement litigation in the US involving the sale of generically similar versions of ‘Protonix’, used to treat gastro-intestinal ulcers and hyperacidity. Sun’s income from operations in the quarter under review stood at ₹3,927 crore, up 13 per cent.